Trial ID or NCT#



not recruiting iconNOT RECRUITING


The purpose of this study is to determine if nitazoxanide in combination with peginterferon alfa-2a and ribavirin is safe and effective in treating chronic hepatitis C in patients that have previously failed to respond to treatment with peginterferon and ribavirin.

Official Title

Phase II, Randomized, Double-blind, Placebo-controlled Study of Nitazoxanide in Combination With Peginterferon Alfa-2a and Ribavirin in Patients With Hepatitis C Who Have Failed to Respond to a Prior Course of Peginterferon and Ribavirin

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No


Ramsey Cheung
Ramsey Cheung
Professor of Medicine (Gastroenterology and Hepatology) at the Palo Alto Veterans Affairs Health Care System

Contact us to find out if this trial is right for you.


Shawna Thunen
(650) 723-5512